OTTAWA, Canada & PITTSBURGH--(BUSINESS WIRE)--Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
Evofem Biosciences, Inc. and Orion Biotechnology Canada Ltd. have entered into a collaboration agreement to evaluate the compatibility and Stability of Orion's novel CCR5 Antagonist , OB-002, in Evofem's Phexxi (lactic acid, citric acid and potassium bitartrate) Vaginal Gelnwith the goal of developing a Multipurpose Prevention Technology (MPT)nproduct candidate for indications including the prevention of HIV in nwomen.
Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of Orion’s lead compound, OB-002, a GPCR analog of CCL5 with best-in-class potency and broad applicability across a range of serious diseases including cancer and
OTTAWA, Canada, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS). OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging its proprietary Drug Discovery Platform.